Broken String Biosciences has appointed Bruce Eaton as Chairman of the Board, with immediate effect. The appointment aligns with the Company’s strategic growth objectives following recent senior leadership changes, to drive global commercialisation of the INDUCE-seq platform.
Bruce has more than 30 years of experience in the biotech sector, spanning operational, business development and corporate strategy roles for both public and private companies. He has founded and successfully grown multiple companies, including I2 Pharmaceuticals and Velocity Sciences. More recently, As Executive Vice President, CTO and CBO for Editas Medicine, Bruce oversaw a multidisciplinary team of more than 100 employees, driving a strategic realignment initiative while leading the company’s R&D programme in sickle cell anaemia. Now focusing his expertise in an advisory capacity, Bruce is currently Independent Director for Renova Therapeutics, and serves as a Strategic Advisor to biotech companies in Gene Therapy and AI drug discovery.
As Chairman of the Board, Bruce will work closely with the company’s leadership team to implement a robust strategy for operational scale-up and commercial expansion for INDUCE-seq. Designed to tackle longstanding regulatory hurdles in the development of gene editing therapeutics, INDUCE-seq provides a universal, unbiased solution to genome-wide DNA break analysis. The commercial strategy will build on recent milestones, including the submission of an FDA Master File2, providing therapeutic developers with a streamlined route to advance novel therapeutic candidates toward IND.
Terry Pizzie, CEO, Broken String Biosciences, said: “Bruce’s expertise in commercial strategy will be invaluable to us as we look to position INDUCE-seq as the gold-standard solution for gene editing off-target assessment. Following the submission of our FDA Master File for INDUCE-seq, we are now uniquely placed to support gene editing teams through IND with unbiased insights into genome integrity.”
Eaton commented: “Gene editing therapeutics have the potential to transform today’s therapeutic landscape, however they are held back by the disparity between regulatory expectation and technological capabilities. INDUCE-seq directly tackles this challenge, providing comprehensive, cell-based assessment of on- and off-target effects. I look forward to working closely with the Board and leadership team, to drive an effective commercial strategy and enable gene editing teams worldwide to confidently progress their candidates towards the clinic.”
Broken String Biosciences is a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines.